An Obvious ‘comity of Errors’: Court Admonishes Motives of Applications Judge, but Agrees with the Result
| DOI | 10.1093/jiplp/jpt027 |
| Date | 21 March 2013 |
| Pages | 339-341 |
| Year | 2013 |
| Published By | Oxford University Press |
Current Intelligence
Patents
BAn obvious ‘Comity of Errors’: Court
admonishes motives of Applications Judge,
but agrees with the result
Apotex Inc v Allergan Inc, 2012 FCA 308, Federal Court of
Appeal, Canada, 23 November 2012
The Federal Court of Appeal upheld a prohibition
order sought by Allergan preventing the Minister of
Health from issuing a Notice of Compliance to Apotex
but admonished the Applications Judge for granting the
prohibition order simply to ‘further his desire to clarify
the jurisprudence’ (Apotex, para 6).
Legal context
The initial proceeding before the Applications Judge
(2012 FC 767) was brought under the Patented Medicines
(Notice of Compliance) Regulations, SOR 93-133, this
being a summary application for judicial review initiated
by the applicant (the patent holder) who seeks to prohibit
the Minister of Health from issuing a Notice of Compli-
ance. Once the generic manufacturer has presented proba-
tive evidence supporting its allegations of anticipation
and obviousness (in this instance), the burden of proof is
on the applicant to establish, on a balance of probabilities,
that those allegations are not justified.
Subsection 5(1) of the Regulations sets out the require-
ments for a ‘generic’ drug company (ie a ‘second person’)
to obtain a notice of compliance from the Minister of
Health for approval of its generic drug:
If a second person files a submission for a notice of com-
pliance in respect of a drug and the submission directly or
indirectly compares the drug with, or makes reference to,
another drug marketed in Canada under a notice of com-
pliance issued to a first person and in respect of which a
patent list has been submitted, the second person shall, in
the submission, with respect to each patent on the register
in respect of the other drug,
(a) state that the second person accepts that the notice of
compliance will not issue until the patent expires; or
(b) allege that
(i) the statement made by the first person under
paragraph 4(4)(d) is false,
(ii) the patent has expired,
(iii) the patent is not valid, or
(iv) no claim for the medicinal ingredient, no claim
for the formulation, no claim for the dosage
form and no claim for the use of the medicinal
ingredient would be infringed by the second
person making, constructing, using or selling the
drug for which the submission is filed.
Subsection6(1)thensetsouthowan‘innovator’drug
company (ie a ‘first person’) must object to such allegations:
A first person may, within 45 days after being served
with a notice of allegation under paragraph 5(3)(a), apply
to a court for an order prohibiting the Minister from
issuing a notice of compliance until after the expiration of
a patent that is the subject of the notice of allegation.
Facts
Under the Regulations, Allergan sought an order prohibiting
the Minister of Health from issuing a Notice of Compliance
(NOC) to Apotex for its generic glaucoma medication
until the expiry of Allergan’s patent. In the Notice of Allega-
tion, Apotex challenged the validity of Allergan’s patent
on the grounds of obviousness and anticipation.
Justice Hughes, the Applications Judge, held that
Apotex’s allegation of invalidity on the grounds of obvi-
ousness was justified (2012 FC 767 at para 189). However,
in separate proceedings, involving the same patent, Justice
Crampton (as he then was) held that:
Allergan has met its burden of establishing, on a balance
of probabilities, that Sandoz’s allegation that the ’764
Patent is invalid on the ground of obviousness is not
justified. (Allergan Inc and others v Canada (Minister of
Health) and Sandoz Canada Inc, 2011 FC 1316 (‘Sandoz’),
para 127).
In other words, if Justice Hughes found the allegations of
obviousness justified it would run contrary to Justice
Crampton’s earlier finding. Therefore in the interests
of judicial comity, Justice Hughes disregarded his own
findings, and granted the prohibition order in favour of
Allergan. At paras 189– 94 he writes:
As is apparent, I would find on the evidence before me
that Apotex’s allegation s as to obviousness are justified ...
That is, however, not the end of the matter.
I must consider the question of comity. Is the evidence
and argument before me ‘different’ from or ‘better’ than
the evidence and argument before Crampton J in Sandoz?
There is no real way to measure ‘different’ or ‘better’. The
evidence and argument is of the same kind. In some cases
Crampton J had unrebutted evidence whereas I have rebut-
ted evidence. The difference in the evidence and argument
is more one of quality to the best that can be discerned
from the record that I have, and this court not having the
Journal of Intellectual Property Law & Practice, 2013, Vol. 8, No. 5 339
#The Author(s) (2013). Published by Oxford University Press. All rights reserved.
Get this document and AI-powered insights with a free trial of vLex and Vincent AI
Get Started for FreeStart Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting